Soleno Therapeutics (NASDAQ: SLNO) shares non-deal roadshow deck

Rhea-AI Filing Summary

Soleno Therapeutics, Inc. is sharing an investor presentation for use in previously scheduled meetings with existing and potential investors as part of a non-deal roadshow hosted by Guggenheim Securities and Piper Sandler on August 18–19, 2025. The slide deck is furnished as Exhibit 99.1 to this current report. The company states that this material, including Exhibit 99.1, is provided under Item 7.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-08-18 2025-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 18, 2025

SOLENO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36593		77-0523891
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification Number)

100 Marine Parkway, Suite 400

Redwood City, CA 94065

(Address of principal executive offices)

(650) 213-8444

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbols		Name of each exchange on which registered
Common Stock, $0.001 par value		SLNO		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 Regulation FD Disclosure

During August 18-19, 2025, senior management of Soleno Therapeutics, Inc. (the “Company”) will participate in previously scheduled meetings with existing and potential investors as part of a non-deal roadshow hosted by Guggenheim Securities and Piper Sandler. A copy of the investor presentation to be used during these meetings is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				SOLENO THERAPEUTICS, INC.
Date: August 18, 2025
				By:		/s/ Anish Bhatnagar
						Anish Bhatnagar
						Chief Executive Officer

FAQ

What did Soleno Therapeutics (SLNO) disclose in this 8-K?

Soleno Therapeutics disclosed that its senior management will participate in a non-deal roadshow on August 18–19, 2025 and that an accompanying investor presentation is being furnished as Exhibit 99.1.

What is the purpose of Soleno Therapeutics' non-deal roadshow?

The roadshow involves previously scheduled meetings with existing and potential investors, hosted by Guggenheim Securities and Piper Sandler, where Soleno’s senior management will use the attached investor presentation.

How is the investor presentation in Exhibit 99.1 legally treated?

The information under Item 7.01, including Exhibit 99.1, is expressly stated as not deemed “filed” for purposes of Section 18 of the Exchange Act and is not automatically subject to that section’s liabilities.

Is the Soleno Therapeutics investor presentation incorporated into other SEC filings?

The company states the presentation will not be deemed incorporated by reference into its Securities Act or Exchange Act filings, except where specifically incorporated by reference in a future filing.

Where can investors find the Soleno Therapeutics roadshow materials?

The materials are included as Exhibit 99.1 – Corporate Presentation to this current report, with a separate Cover Page Interactive Data File identified as Exhibit 104.

Who signed the Soleno Therapeutics 8-K related to the roadshow?

The report was signed on behalf of Soleno Therapeutics, Inc. by Anish Bhatnagar, who is identified as the company’s Chief Executive Officer.